48 Projects have been approved under the Production Linked Incentive Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India

48 Projects have been approved under the Production Linked Incentive Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India

Under the Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India, 48 projects have been approved. Details in respect of applicants/beneficiaries under the scheme are at Annexure.

The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on single source. Products notified and approved under the scheme prior to commencement of production under the PLI scheme were primarily imported. As of December 2024, against an investment commitment of ₹3,938.5 crore over the period of six years, investment of ₹4,254 crore has already been made under the scheme. As a result of the scheme, cumulative sales of ₹1,556 crore have been reported over the period from the beginning of the scheme till December 2024, including exports of ₹412 crore, thereby avoiding imports worth ₹1,144 crore and creating domestic manufacturing capacity for 25 identified KSMs/DIs/APIs.

Number of measures were taken to enhance awareness and encourage participation in the scheme at the time of the launch of the scheme and various rounds of invitation of applications under it, including the following:

Annexure

Details regarding applicants/beneficiaries under the PLI Scheme for promotion of domestic manufacturing of critical KSMs/DIs/APIs in India

S. No.

Name of the applicant

Approved product

Lyfius Pharma Pvt. Ltd.

Penicillin G

Karnataka Antibiotics and Pharmaceuticals Ltd.

7 ACA

Kinvan Pvt. Ltd.

Clavulanic Acid

Orchid Bio-Pharma Ltd.

7 ACA

Macleods Pharmaceutical Ltd.

Rifampicin

Natural Biogenex Pvt. Ltd.

Betamethasone

Natural Biogenex Pvt. Ltd.

Dexamethasone

Natural Biogenex Pvt. Ltd.

Prednisolone

SymbiotecPharmalab Pvt. Ltd.

Prednisolone

Emmennar Pharma Pvt. Ltd.

1,1 Cyclohexane Diacetic Acid (CDA)

Granules India Ltd.

Dicyandiamide (DCDA)

Hindys Lab Pvt. Ltd.

1,1 Cyclohexane Diacetic Acid (CDA)

Meghmani LLP

Para Amino Phenol

Sadhana Nitro Chem Ltd.

Para Amino Phenol

Alta Laboratories Ltd.

Aspirin

Amoli Organics Pvt. Ltd.

Diclofenac sodium

Anasia Lab Pvt. Ltd.

Losartan

Anasia Lab Pvt. Ltd.

Olmesartan

Andhra Organics Ltd.

Olmesartan

Andhra Organics Ltd.

Sulfadiazine

Andhra Organics Ltd.

Telmisartan

Aviran Pharmachem Pvt. Ltd.

Artesunate

Centrient Pharmaceuticals India Pvt. Ltd.

Atorvastatin

Dasami Lab Pvt. Ltd.

Carbamazepine

Dasami Lab Pvt. Ltd.

Oxcarbazepine

Global Pharma Healthcare Pvt. Ltd.

Ofloxacin

Globela Industries Pvt. Ltd

Norfloxacin

Globela Industries Pvt. Ltd

Ofloxacin

Hazelo Lab Pvt. Ltd.

Vitamin B6

Hetero Drugs Ltd.

Carbidopa

Hetero Drugs Ltd.

Levodopa

Hetero Drugs Ltd.

Levofloxacin

Hetero Drugs Ltd.

Oxcarbazepine

Hindys Lab Pvt. Ltd.

Acyclovir

Honour Lab Ltd.

Levetiracetam

Honour Lab Ltd.

Lopinavir

Honour Lab Ltd.

Valsartan

Honour Lab Ltd.

Vitamin B6

K. P. Manish Global Ingredients Pvt. Ltd.

Artesunate

Kreative Actives Pvt. Ltd.

Diclofenac sodium

Lifetech Sciences

Ritonavir

MSN Life Sciences Pvt. Ltd.

Levofloxacin

Rajasthan Antibiotics Ltd.

Meropenem

RMC Performance Chemicals Pvt. Ltd.

Aspirin

Sudarshan Pharma Industries Ltd.

Vitamin B1

Sudarshan Pharma Industries Ltd.

Vitamin B6

Vital Laboratories Pvt. Ltd.

Levofloxacin

Vital Laboratories Pvt. Ltd.

Ofloxacin

 

This information was given by the Union Minister of State for Chemicals and Fertilizers Smt Anupriya Patel in Rajya Sabha in a written reply to a question today.

*****